Literature DB >> 35505819

Hepatitis C Virus Treatment and Solid Organ Transplantation.

Ronit Patnaik1, Eugenia Tsai1,2.   

Abstract

Hepatitis C virus (HCV) infection is a common indication for liver transplantation. If the patient's HCV is untreated prior to liver transplant, infection of the allograft is nearly universal and can lead to graft failure. The demand for deceased-donor organ transplantation continues to surpass the available supply of donor organs. Waitlist mortality remains an important concern, and several strategies have been enacted to increase organ supply, such as using high-risk donors, including those who are HCV positive. The development of safe and highly effective HCV therapy with direct-acting antiviral agents has revolutionized the management of liver transplant candidates and transplantrecipients. Moreover, thenewer antiviral therapieshave paved the road for use of HCV-viremic organs, effectively expanding the donor pool and changing the landscape of solid organ transplantation. This article reviews the data on HCV treatment prior to and after organ transplantation.
Copyright © 2022, Gastro-Hep Communications, Inc.

Entities:  

Keywords:  Chronic hepatitis C virus; direct-acting antiviral; hepatitis C virus–positive donor; liver transplantation; solid organ transplantation

Year:  2022        PMID: 35505819      PMCID: PMC9053510     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


  83 in total

1.  Elderly recipients of hepatitis C positive renal allografts can quickly develop liver disease.

Authors:  Tanya R Flohr; Hugo Bonatti; Tjasa Hranjec; Doug S Keith; Peter I Lobo; Sean C Kumer; Timothy M Schmitt; Robert G Sawyer; Timothy L Pruett; John P Roberts; Kenneth L Brayman
Journal:  J Surg Res       Date:  2011-11-19       Impact factor: 2.192

2.  Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.

Authors:  Michael Manns; Didier Samuel; Edward J Gane; David Mutimer; Geoff McCaughan; Maria Buti; Martín Prieto; José Luis Calleja; Markus Peck-Radosavljevic; Beat Müllhaupt; Kosh Agarwal; Peter Angus; Eric M Yoshida; Massimo Colombo; Mario Rizzetto; Hadas Dvory-Sobol; Jill Denning; Sarah Arterburn; Phillip S Pang; Diana Brainard; John G McHutchison; Jean-François Dufour; Hans Van Vlierberghe; Bart van Hoek; Xavier Forns
Journal:  Lancet Infect Dis       Date:  2016-02-18       Impact factor: 25.071

Review 3.  Nucleic acid testing (NAT) of organ donors: is the 'best' test the right test? A consensus conference report.

Authors:  A Humar; M Morris; E Blumberg; R Freeman; J Preiksaitis; B Kiberd; E Schweitzer; S Ganz; A Caliendo; J P Orlowski; B Wilson; C Kotton; M Michaels; S Kleinman; S Geier; B Murphy; M Green; M Levi; G Knoll; Dorry L Segev; S Brubaker; R Hasz; D J Lebovitz; D Mulligan; K O'Connor; T Pruett; M Mozes; I Lee; F Delmonico; S Fischer
Journal:  Am J Transplant       Date:  2010-01-29       Impact factor: 8.086

4.  Transplantation of hepatitis C-positive livers in hepatitis C-positive patients is equivalent to transplanting hepatitis C-negative livers.

Authors:  C E Marroquin; G Marino; P C Kuo; J S Plotkin; V K Rustgi; A D Lu; E Edwards; S Taranto; L B Johnson
Journal:  Liver Transpl       Date:  2001-09       Impact factor: 5.799

5.  A model to estimate the probability of human immunodeficiency virus and hepatitis C infection despite negative nucleic acid testing among increased-risk organ donors.

Authors:  Pallavi D Annambhotla; Brian M Gurbaxani; Matthew J Kuehnert; Sridhar V Basavaraju
Journal:  Transpl Infect Dis       Date:  2017-03-27       Impact factor: 2.228

6.  Donor hepatitis-C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation.

Authors:  Showkat A Haji; Randall C Starling; Robin K Avery; Steven Mawhorter; E Murat Tuzcu; Paul Schoenhagen; Daniel J Cook; Norman B Ratliff; Patrick M McCarthy; James B Young; Mohamad H Yamani
Journal:  J Heart Lung Transplant       Date:  2004-03       Impact factor: 10.247

7.  Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study.

Authors:  Luca Saverio Belli; Marina Berenguer; Paolo Angelo Cortesi; Mario Strazzabosco; Susanne-Rasoul Rockenschaub; Silvia Martini; Cristina Morelli; Francesca Donato; Riccardo Volpes; Georges-Philippe Pageaux; Audrey Coilly; Stefano Fagiuoli; Giuliana Amaddeo; Giovanni Perricone; Carmen Vinaixa; Gabriela Berlakovich; Rita Facchetti; Wojciech Polak; Paolo Muiesan; Christophe Duvoux
Journal:  J Hepatol       Date:  2016-05-17       Impact factor: 25.083

8.  Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.

Authors:  Fred Poordad; Franco Felizarta; Armen Asatryan; Mark S Sulkowski; Robert W Reindollar; Charles S Landis; Stuart C Gordon; Steven L Flamm; Michael W Fried; David E Bernstein; Chih-Wei Lin; Ran Liu; Sandra S Lovell; Teresa I Ng; Jens Kort; Federico J Mensa
Journal:  Hepatology       Date:  2017-04-10       Impact factor: 17.425

9.  Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.

Authors:  Nancy Reau; Paul Y Kwo; Susan Rhee; Robert S Brown; Kosh Agarwal; Peter Angus; Edward Gane; Jia-Horng Kao; Parvez S Mantry; David Mutimer; K Rajender Reddy; Tram T Tran; Yiran B Hu; Abhishek Gulati; Preethi Krishnan; Emily O Dumas; Ariel Porcalla; Nancy S Shulman; Wei Liu; Suvajit Samanta; Roger Trinh; Xavier Forns
Journal:  Hepatology       Date:  2018-07-25       Impact factor: 17.425

10.  Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.

Authors:  Jordan J Feld; Ira M Jacobson; Christophe Hézode; Tarik Asselah; Peter J Ruane; Norbert Gruener; Armand Abergel; Alessandra Mangia; Ching-Lung Lai; Henry L Y Chan; Francesco Mazzotta; Christophe Moreno; Eric Yoshida; Stephen D Shafran; William J Towner; Tram T Tran; John McNally; Anu Osinusi; Evguenia Svarovskaia; Yanni Zhu; Diana M Brainard; John G McHutchison; Kosh Agarwal; Stefan Zeuzem
Journal:  N Engl J Med       Date:  2015-11-16       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.